Zambon launches Xadago first in Germany, next in Switzerland
This article was originally published in Scrip
Zambon has launched Xadago (safinamide), an add-on therapy for treating idiopathic Parkinson's disease in its first market, Germany. It is the first new chemical entity to be approved for Parkinson's in 10 years.
You may also be interested in...
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.